{"id":45316,"date":"2025-10-30T22:00:34","date_gmt":"2025-10-30T14:00:34","guid":{"rendered":"https:\/\/flcube.com\/?p=45316"},"modified":"2025-10-30T22:00:35","modified_gmt":"2025-10-30T14:00:35","slug":"pharmaron-expands-cro-footprint-with-82-5-acquisition-of-biortus-in-200-m-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45316","title":{"rendered":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal"},"content":{"rendered":"\n<p>China\u2011based Pharmaron Beijing Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/3759:HKG\">HKG: 3759<\/a>) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.<\/p>\n\n\n\n<p><strong>Strategic Rationale Behind the Deal<\/strong><br>Biortus, a leading Chinese contract research organization (CRO), specializes in structural biology\u2011related R&amp;D and boasts a strong Cryo\u2011Electron Microscopy (Cryo\u2011EM) platform. The acquisition is expected to enrich Pharmaron\u2019s portfolio of cutting\u2011edge biopharmaceutical services, enabling the company to offer end\u2011to\u2011end solutions for drug discovery and development across biotech and pharma clients.<\/p>\n\n\n\n<p><strong>Financial and Operational Highlights<\/strong><br>Biortus was incorporated in China with a registered capital of RMB\u202f52,333,424. Its Cryo\u2011EM technology provides high\u2011resolution structural insights that are critical for drug target validation and affinity maturation. Following the deal, Pharmaron plans to integrate Biortus\u2019s CRO team and infrastructure, creating synergies that could accelerate portfolio development and shorten time\u2011to\u2011market for partner drugs.<\/p>\n\n\n\n<p><strong>Market Impact and Outlook<\/strong><br>The transaction underscores Pharmaron\u2019s strategy to grow its CRO business in a rapidly expanding Chinese biotech ecosystem. Analysts note that the combined entity\u2019s enhanced Cryo\u2011EM capabilities could position Pharmaron as a preferred external partner for global pharma firms seeking advanced structural biology services, potentially driving revenue growth in the coming fiscal years.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102801941_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102801941_c.\"><\/object><a id=\"wp-block-file--media-30d2486f-3cc7-478e-b453-4ddfe6f76ccc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102801941_c.pdf\">2025102801941_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102801941_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-30d2486f-3cc7-478e-b453-4ddfe6f76ccc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45319,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4417,19,1501,768],"class_list":["post-45316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biortus-biosciences","tag-cro-cmo-cdmo","tag-hkg-3759","tag-pharmaron"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45316\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45316\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T14:00:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T14:00:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal\",\"datePublished\":\"2025-10-30T14:00:34+00:00\",\"dateModified\":\"2025-10-30T14:00:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3002-1.webp\",\"keywords\":[\"Biortus Biosciences\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 3759\",\"Pharmaron\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45316#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45316\",\"name\":\"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3002-1.webp\",\"datePublished\":\"2025-10-30T14:00:34+00:00\",\"dateModified\":\"2025-10-30T14:00:35+00:00\",\"description\":\"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45316\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3002-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3002-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45316#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45316","og_locale":"en_US","og_type":"article","og_title":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal","og_description":"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.","og_url":"https:\/\/flcube.com\/?p=45316","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T14:00:34+00:00","article_modified_time":"2025-10-30T14:00:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45316#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45316"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal","datePublished":"2025-10-30T14:00:34+00:00","dateModified":"2025-10-30T14:00:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45316"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45316#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","keywords":["Biortus Biosciences","CRO \/ CMO \/ CDMO","HKG: 3759","Pharmaron"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45316#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45316","url":"https:\/\/flcube.com\/?p=45316","name":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45316#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45316#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","datePublished":"2025-10-30T14:00:34+00:00","dateModified":"2025-10-30T14:00:35+00:00","description":"China\u2011based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October\u202f28,\u202f2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB\u202f1.346\u202fbillion (\u2248\u202fUS\u202f$200\u202fmillion). The transaction will make Biortus a Pharmaron subsidiary and deepen the group\u2019s footprint in contract research services that leverage structural biology expertise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45316#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45316"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45316#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","width":1080,"height":608,"caption":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45316#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200\u202fM Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3002-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45316"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45316\/revisions"}],"predecessor-version":[{"id":45321,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45316\/revisions\/45321"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45319"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}